Loading...

PE/Cyanine7 anti-mouse CD279 (PD-1) Antibody

Pricing & Availability
Clone
RMP1-30 (See other available formats)
Regulatory Status
RUO
Other Names
Programmed Death-1, CD279, PDCD1
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
RMP1-30_PECy7_021808
Con A-stimulated (day-3) Balb/c mouse splenocytes stained with RMP1-30 PE/Cyanine7
  • RMP1-30_PECy7_021808
    Con A-stimulated (day-3) Balb/c mouse splenocytes stained with RMP1-30 PE/Cyanine7
Compare all formats See PE/Cyanine7 spectral data
Cat # Size Price Quantity Check Availability Save
109109 25 µg 88€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
109110 100 µg 234€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD279 is a 50-55 kD immunoglobulin superfamily member also known as programmed death-1 (PD-1). PD-1 is expressed on a subset of CD4-CD8- thymocytes and on activated T and B cells. PD-1 is thought to be involved in lymphocyte clonal selection and peripheral tolerance. The PD-1 ligands, PD-L1 (also known as B7-H1) and PD-L2 (B7-DC), are members of the B7 immunoglobulin superfamily.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse PD-1 transfected BHK cells
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE/Cyanine7 under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The CD279 antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is =1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

The RMP1-30 antibody does not block the binding of PD-1 to B7-H1 and B7-DC1.

Additional Product Notes
BioLegend is in the process of converting the name PE/Cy7 to PE/Cyanine7. The dye molecule remains the same, so you should expect the same quality and performance from our PE/Cyanine7 products. Please contact Technical Service if you have any questions.
Application References

(PubMed link indicates BioLegend citation)
  1. Matsumoto K, et al. 2004. J. Immunol. 172:2530.
  2. Raimondi G, et al. 2006. J. Immunol. 176:2808. (FC) PubMed
  3. King IL, et al. 2009. J. Exp Med 206:1001. (FC) PubMed
Product Citations
  1. Lindenstrøm T, et al. 2013. J Immunol. 190:6311. PubMed
  2. Vanderleyden I, et al. 2020. Cell Rep. 30:611. PubMed
  3. Singer M et al. 2016. Cell. 166(6):1500-1511 . PubMed
  4. Gern BH, et al. 2021. Cell Host Microbe. 29(4):594-606.e6. PubMed
  5. Turner JS et al. 2018. Cell reports. 25(6):1395-1403 . PubMed
  6. Blecher-Gonen R, et al. 2019. Cell Syst. 8:109. PubMed
  7. Andrade MS, et al. 2022. JCI Insight. 7:. PubMed
  8. Webb LMC, et al. 2021. Aging Cell. 20:e13295. PubMed
  9. Shi J, et al. 2018. Immunity. 49:264. PubMed
  10. Wu M, et al. 2021. Nat Commun. 12:3500. PubMed
  11. Low MSY, et al. 2019. Cell Reports. 29(9):2634-2645.e5. PubMed
  12. McLane LM, et al. 2021. Cell Reports. 35(6):109120. PubMed
  13. Acharya N, et al. 2020. Immunity. 53(3):658-671.e6. PubMed
  14. Pérez‐Mazliah D et al. 2017. EBioMedicine. 24:216-230 . PubMed
  15. Elsner RA, et al. 2020. Cell Reports. 29(9):2796-2809.e5.. PubMed
  16. Mohrs I 2009. J Exp Med. 206:1001. PubMed
  17. Montes de Oca R, et al. 2021. Mol Cancer Ther. 20:1941. PubMed
  18. Chen JS, et al. 2022. Sci Immunol. 7:eabl5652. PubMed
  19. Biram A, et al. 2020. Cell Rep. 30:1910. PubMed
  20. Dangi T, et al. 2020. Curr Protoc Immunol. 130:e99. PubMed
  21. Suah AN, et al. 2021. J Clin Invest. 131:. PubMed
  22. Yu AI, et al. 2020. Cell Rep. 107471:31. PubMed
  23. Hilpert C, et al. 2016. J Immunol. 197: 2780 - 2786. PubMed
  24. Panciera T, et al. 2016. Cell Stem Cell. 19:725-737. PubMed
  25. Siddiqui I et al. 2019. Immunity. 50(1):195-211 . PubMed
  26. Stump CT, et al. 2021. Open Biol. 11:210245. PubMed
  27. Jeon S, et al. 2013. J Immunol. 190:6277. PubMed
  28. Hossain DMS, et al. 2018. J Clin Invest. 128:644. PubMed
  29. Verghese DA, et al. 2018. JCI Insight. 3:. PubMed
  30. Chen Z et al. 2019. Immunity. 51(5):840-855 . PubMed
  31. Myers DR et al. 2019. Cell reports. 27(6):1858-1874 . PubMed
  32. Wang Y, et al. 2021. Cell Rep. 35:108948. PubMed
  33. Sullivan JA, et al. 2020. Cell Rep. 30:1039. PubMed
  34. Jing Y, et al. 2020. Sci Adv. 6:eaax9455. PubMed
  35. Yadava K et al. 2019. Elife. 8 pii: e44821. PubMed
  36. , et al. 2021. Eur J Immunol. 51:2708. PubMed
  37. Fu G, et al. 2021. Nature. 595:724. PubMed
  38. Gary E, et al. 2020. Vaccine. 3821:38. PubMed
  39. Volberding PJ, et al. 2021. Cell Reports. 35(8):109160. PubMed
  40. Ringel AE, et al. 2020. Cell. 183(7):1848-1866.e26. PubMed
  41. Van Gool F, et al. 2019. Immunity. 50:362. PubMed
  42. Jain RW, et al. 2018. Cell Rep. 25:3342. PubMed
  43. Alameh MG, et al. 2021. Immunity. 54:2877. PubMed
  44. Trefzer A, et al. 2021. Cell Reports. 34(6):108748. PubMed
  45. Gabriel SS, et al. 2021. Immunity. 54(8):1698-1714.e5. PubMed
  46. Jin C, et al. 2019. Cell. 176:998. PubMed
  47. Ying Zhang et al. 2017. Cancer cell. 32(3):377-391 . PubMed
  48. Hilpert C, et al. 2019. J Immunol. 203:3068. PubMed
  49. Chatterjee S et al. 2017. Cell metabolism. 27(1):85-100 . PubMed
  50. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  51. Zotos D, et al. 2021. Nat Commun. 12:7160. PubMed
  52. Biram A, et al. 2020. Bio Protoc. e3562:10. PubMed
  53. Vardhana SA, et al. 2020. Nat Immunol. 1.584722222. PubMed
  54. Etzerodt A, et al. 2019. J Exp Med. 216:2394. PubMed
  55. Xiao S, et al. 2020. Cell Reports. 32(2):107892. PubMed
  56. Wu S, et al. 2021. Nat Cancer. 2:189. PubMed
  57. Evgin L, et al. 2020. Nat Commun. 2.671527778. PubMed
  58. Benci JL et al. 2019. Cell. 178(4):933-948 . PubMed
  59. Woodworth J, et al. 2014. J Immunol. 192:3247. PubMed
  60. Miyauchi K, et al. 2016. Nat Immunol. 17:1447-1458. PubMed
  61. Benci JL et al. 2016. Cell. 167(6):1540-1554 . PubMed
  62. Sema Kurtulus et al. 2018. Immunity. 50(1):181-194 . PubMed
  63. Fan MY et al. 2018. Cell reports. 25(5):1204-1213 . PubMed
  64. Chen Y, et al. 2021. Nat Immunol. 22:996. PubMed
  65. Miyauchi K, et al. 2021. Nat Commun. 12:3789. PubMed
  66. Chen Z, et al. 2021. Cell. 184(5):1262-1280.e22. PubMed
  67. Filskov J, et al. 2019. Sci Rep. 9:14085. PubMed
  68. Burger ML, et al. 2021. Cell. 184:4996. PubMed
  69. McPhee C, et al. 2013. J Immunol. 191:4581. PubMed
  70. Liu D, et al. 2021. Immunity. 54:2245. PubMed
  71. Smith LK, et al. 2021. Elife. 10:. PubMed
  72. Xu C, et al. 2021. Cell Reports. 35(11):109235. PubMed
  73. Dubrot J, et al. 2021. Immunity. 54(3):571-585.e6. PubMed
  74. Lederer K, et al. 2020. Immunity. 53(6):1281-1295.e5. PubMed
  75. Zander R, et al. 2020. Immunity. 51(6):1028-1042.e4.. PubMed
  76. Nawaf M, et al. 2017. J Immunol. 10.4049/jimmunol.1700088. PubMed
  77. Song W, et al. 2022. Immunity. 55:290. PubMed
  78. Christensen D, et al. 2016. Mucosal Immunol. 10.1038/mi.2016.28. PubMed
RRID
AB_572016 (BioLegend Cat. No. 109109)
AB_572017 (BioLegend Cat. No. 109110)

Antigen Details

Structure
Ig superfamily, 50-55 kD
Distribution

Subset of double negative thymocytes, activated T and B cells

Function
Lymphocyte clonal selection, peripheral tolerance
Ligand/Receptor
PD-L1 (B7-H1), PD-L2
Cell Type
B cells, T cells, Thymocytes, Tregs
Biology Area
Apoptosis/Tumor Suppressors/Cell Death, Cancer Biomarkers, Cell Biology, Immunology, Inhibitory Molecules
Molecular Family
CD Molecules, Immune Checkpoint Receptors
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Agata Y, et al. 1996. Int. Immunol. 8:765.
3. Nishimura H, et al. 2001. Science 291:319.
4. Ishida Y, et al. 1992. EMBO J. 11:3887.

Gene ID
18566 View all products for this Gene ID
UniProt
View information about CD279 on UniProt.org

Related FAQs

There are no FAQs for this product.
Go To Top Version: 1    Revision Date: 11/30/2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account